[1]
|
E. A. Ashley, Y.Lubell, N. J. White and P. Turner, “Antimicrobial Susceptibility of Bacterial Isolates from Community Acquired Infections in Sub-Saharan Africa and Asian Low and Middle Income Countries,” Tropical Medicine and International Health, Vol. 16, No. 9, 2011, pp. 1167-1179.
http://dx.doi.org/10.1111/j.1365-3156.2011.02822.x
|
[2]
|
D. Faith, M. Villanueva, E. Thelma, D. Tupasi, G. Homer, M. D.Abiad, Q. Benilda, M. Baello, C. Rowena and D. Cardano, “Extended Spectrum β-Lactamase Production among Escherichia coli and Klebsiella spp.,” Philippines Journal Microbiological Infectious Diseases, Vol. 32, No. 3, 2003, pp. 103-108.
|
[3]
|
R. Canton, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero and T. M. Coque, “Prevalence and Spread of Extended-Spectrum Betalactamase-Producing Enterobacteriaceae in Europe,” Clinical Microbiology and Infection, Vol. 14, Suppl. 1, 2008, pp. 144-153.
http://dx.doi.org/10.1111/j.1469-0691.2007.01850.x
|
[4]
|
S. Kotapati, J. L. Kuti and C. H. Nightingale, “Clinical Implications of Extended Spectrum b-Lactamase (ESBL) Producing Klebsiella Species and Escherichia coli on Cefepime Effectiveness,” Journal of Infection, Vol. 51, No. 3, 2005, pp. 211-217.
|
[5]
|
H. Y. Sun, S. Y. Chen, S. C. Chang, S. C. Pan, C. P. Su, and Y. C. Chen, “Community-Onset Escherichia coli and Klebsiella pneumoniae bacteremia: Influence of Health Care Exposure on Antimicrobial Susceptibility,” Diagnostic Microbiology and Infectious Disease, Vol. 55, No. 2, 2006, pp. 135-141.
http://dx.doi.org/10.1016/j.diagmicrobio.2006.01.004
|
[6]
|
D. L. Paterson and R. A. Bonomo, “Extended-Spectrum β-Lactamases: A Clinical Update,” Clinical Microbiology Reviews, Vol. 18, No. 4, 2005, pp. 657-686.
http://dx.doi.org/10.1128/CMR.18.4.657-686.2005
|
[7]
|
M. Gniadkowski, “Evolution and Epidemiology of Extended Spectrum β-Lactamases (ESBLs) and ESBL-Producing Microorganisms,” Clinical Microbiology and Infection, Vol. 7, No. 11, 2001, pp. 597-608.
http://dx.doi.org/10.1046/j.1198-743x.2001.00330.x
|
[8]
|
S. Nathisuwan, D. S. Burgess and J. S. Lewis, “Extended-Spectrum Beta-Lactamases: Epidemiology, Detection, and Treatment,” Pharmacotherapy, Vol. 21, No. 8, 2001, pp. 920-928.
http://dx.doi.org/10.1592/phco.21.11.920.34529
|
[9]
|
M. F. Lin, M. L. Huang and S.H. Lai, “Risk Factors in the Acquisition of Extended-Spectrum Beta-Lactamase Klebsiella pneumoniae: A Case-Control Study in a District Teaching Hospital in Taiwan,” The Journal of Hospital Infection, Vol. 53, No. 1, 2003, pp. 39-45.
http://dx.doi.org/10.1053/jhin.2002.1331
|
[10]
|
J. Tham, I. Odenholt, M. Walder, A. Brolund, J. Ahl and E. Melander, “Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Patients with Travellers’ Diarrhoea,” Scandavanian Journal of Infectious Diseases, Vol. 42, No. 4, 2010, pp. 275-280.
http://dx.doi.org/10.3109/00365540903493715
|
[11]
|
F. Ndugulile, R. Jureen, S. H. W. Urassa and N. Langeland, “Extended Spectrum β-Lactamases among Gram-Negative Bacteria of Nosocomial Origin from an Intensive Care Unit of a Tertiary Health Facility in Tanzania,” BMC Infectious Diseases, Vol. 5, 2005, p. 86.
http://dx.doi.org/10.1186/1471-2334-5-86
|
[12]
|
K. Bush, “Extended-Spectrum Beta-Lactamases in North America, 1987-2006,”Clinical Microbiology and Infection, Vol. 14, Suppl. 1, 2008, pp. 134-143.
http://dx.doi.org/10.1111/j.1469-0691.2007.01848.x
|
[13]
|
O. O. Soge, A. M. Queenan, K. K. Ojo, B. A. Adeniyi and M. C. Roberts, “CTX-M-15 Extended-Spectrum (beta)-Lactamase from Nigerian Klebsiella pneumoniae,” The Journal of Antimicrobial Chemotherapy, Vol. 57, No.1, 2006, pp. 24-30.
http://dx.doi.org/10.1093/jac/dki429
|
[14]
|
R. A. Afunwa, D. C. Odimegwu, R. I. Iroha and C. O. Esimone, “Antimicrobial Resistance Status and Prevalence Rates of Extended Spectrum Beta-Lactamase Producers Isolated from a Mixed Human Population,” Bosnian Journal of Basic Medical Sciences, Vol. 11, No. 2, 2011, pp. 91-96.
|
[15]
|
Clinical and Laboratory Standards Institute (CLSI), “Performance Standards for Antimicrobial Susceptibility Testing,” 17th Information Supplement, 17th Edition, Approved Standard M100-S17, Clinical and Laboratory Standards Institute, Wayne, 2007.
|
[16]
|
The European Committee on Antimicrobial Susceptibility Testing—EUCAST. http://www.eucast.org
|
[17]
|
E. Lautenbach, J. B. Patel, W. B. Bilker P. H. Edelstein and N. O. Fishman, “Extended-Spectrum β-Lactamase- Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors for Infection and Impact of Resistance on Outcomes,” Clinical Infectious Diseases, Vol. 32, No. 8 2001, pp. 1162-1171. http://dx.doi.org/10.1086/319757
|
[18]
|
R. Tsay, L. K. Siu, C. Fung and F. Chang, “Characteristics of Bacteremia Between Community-Acquired and Nosocomial Klebsiella pneumoniae Infection Risk Factor for Mortality and the Impact of Capsular Serotypes as a Herald for Community-Acquired Infection,” Archives of Internal Medicine, Vol. 162, No. 9, 2002, pp. 1021-1027.
http://dx.doi.org/10.1001/archinte.162.9.1021
|
[19]
|
C. Struve and K. A. Krogfelt, “Pathogenic Potential of Environmental Klebsiella pneumoniae Isolates,” Environmental Microbiology, Vol. 6, No. 6, 2004, pp. 584-590. http://dx.doi.org/10.1111/j.1462-2920.2004.00590.x
|
[20]
|
K. Serefhanoglu, H. Turan, F. E. Timurkaynak and H. Arslan, “Bloodstream Infections Caused by ESBL-Producing E. coli and K. pneumoniae: Risk Factors for Multidrug-Resistance,” Brazilian Journal of Infectious Diseases, Vol. 13, No. 6, 2009 pp. 403-407.
http://dx.doi.org/10.1590/S1413-86702009000600003
|
[21]
|
D. L. Paterson, “Resistance in Gram-Negative Bacteria: Enterobacteriaceae,” American Journal of Medicine, Vol. 119, No. 6, 2006, pp. S20-28.
|
[22]
|
Z. Q. Wei, Y. G. Chen, Y. S. Yu, W. X. Lu and L. J. Li. “Nosocomial Spread of Multi-Resistant Klebsiella pneumoniae Containing a Plasmid Encoding Multiple β-Lactamases,” Journal of Medical Microbiology, Vol. 54 No. 9, 2005 pp. 885-888.
http://dx.doi.org/10.1099/jmm.0.46151-0
|